O	0	9	Detecting
O	10	13	and
O	14	22	treating
B-Disease	23	34	retinopathy
O	35	37	in
O	38	46	patients
O	47	51	with
B-Disease	52	56	type
I-Disease	57	58	I
I-Disease	59	67	diabetes
I-Disease	68	76	mellitus
O	76	77	.

O	78	85	Savings
O	86	96	associated
O	97	101	with
O	102	110	improved
O	111	125	implementation
O	126	128	of
O	129	136	current
O	137	147	guidelines
O	147	148	.

O	149	157	American
O	158	165	Academy
O	166	168	of
O	169	182	Ophthalmology
O	182	183	.

B-Disease	185	193	Diabetic
I-Disease	194	205	retinopathy
O	206	208	is
O	209	212	the
O	213	220	leading
O	221	226	cause
O	227	229	of
B-Symptom	230	238	acquired
I-Symptom	239	248	blindness
O	249	254	among
B-Characteristic	255	264	Americans
I-Characteristic	265	267	of
I-Characteristic	268	275	working
I-Characteristic	276	279	age
O	279	280	.

O	281	284	The
O	285	294	resulting
O	295	303	economic
O	304	307	and
O	308	316	societal
O	317	324	burdens
O	325	328	are
O	329	331	of
O	332	340	profound
O	341	350	magnitude
O	350	351	.

O	352	365	Epidemiologic
O	366	369	and
O	370	378	clinical
O	379	385	trials
O	386	390	data
O	391	395	were
O	396	400	used
O	401	403	to
O	404	411	analyze
O	412	415	the
O	416	422	impact
O	423	425	of
O	426	434	improved
O	435	446	recruitment
O	447	449	of
O	450	458	patients
O	459	463	with
B-Disease	464	468	Type
I-Disease	469	470	I
I-Disease	471	479	diabetes
I-Disease	480	488	mellitus
O	489	493	into
O	494	503	screening
O	504	507	and
O	508	517	treatment
O	518	526	programs
O	526	527	.

O	528	531	The
O	532	540	analysis
O	541	550	predicted
O	551	557	annual
O	558	565	savings
O	566	568	of
O	569	570	$
O	570	573	101
O	573	574	.
O	574	575	0
O	576	583	million
O	584	587	and
O	588	590	47
O	590	591	,
O	591	594	374
O	595	601	person
O	601	602	-
O	602	607	years
O	607	608	-
O	608	613	sight
O	614	616	at
O	617	620	the
O	621	630	currently
O	631	640	estimated
O	641	643	60
O	643	644	%
O	645	654	screening
O	655	658	and
O	659	668	treatment
O	669	683	implementation
O	684	689	level
O	689	690	.

O	691	693	If
O	694	697	all
O	698	706	patients
O	707	715	received
O	716	727	appropriate
B-Anatomy	728	731	eye
O	732	736	care
O	736	737	,
O	738	741	the
O	742	751	predicted
O	752	759	savings
O	760	766	exceed
O	767	770	167
O	770	771	.
O	771	772	0
O	773	780	million
O	781	784	and
O	785	787	79
O	787	788	,
O	788	791	236
O	792	798	person
O	798	799	-
O	799	804	years
O	804	805	-
O	805	810	sight
O	810	811	.

O	812	825	Approximately
O	826	829	two
O	830	836	thirds
O	837	839	of
O	840	843	all
O	844	851	savings
O	852	858	result
O	859	863	from
O	864	873	treatment
O	874	876	of
B-Disease	877	890	proliferative
I-Disease	891	899	diabetic
I-Disease	900	911	retinopathy
O	911	912	,
O	913	918	while
O	919	925	nearly
O	926	929	one
O	930	935	third
O	936	942	arises
O	943	947	from
O	948	957	treatment
O	958	960	of
B-Disease	961	971	clinically
I-Disease	972	983	significant
I-Disease	984	991	macular
I-Disease	992	997	edema
O	997	998	.

O	999	1009	Additional
O	1010	1017	savings
O	1018	1020	of
O	1021	1022	$
O	1022	1026	9571
O	1027	1030	are
O	1031	1039	realized
O	1040	1044	with
O	1045	1049	each
O	1050	1061	recruitment
O	1062	1064	of
O	1065	1066	a
O	1067	1072	newly
O	1073	1082	diagnosed
O	1083	1090	patient
O	1091	1095	with
B-Disease	1096	1104	diabetes
O	1104	1105	.

O	1106	1116	Initiating
O	1117	1126	screening
O	1127	1138	immediately
O	1139	1143	upon
O	1144	1153	diagnosis
O	1154	1156	of
B-Disease	1157	1165	diabetes
O	1165	1166	,
O	1167	1173	rather
O	1174	1178	than
O	1179	1182	the
O	1183	1192	currently
O	1193	1204	recommended
O	1205	1206	5
O	1206	1207	-
O	1207	1211	year
O	1212	1220	deferral
O	1220	1221	,
O	1222	1227	would
O	1228	1230	be
O	1231	1235	cost
O	1236	1245	effective
O	1246	1248	if
O	1249	1250	1
O	1251	1261	additional
O	1262	1272	individual
O	1273	1275	in
O	1276	1278	56
O	1279	1283	were
O	1284	1293	recruited
O	1293	1294	.

O	1295	1299	This
O	1300	1305	model
O	1306	1314	suggests
O	1315	1319	that
O	1320	1328	improved
O	1329	1337	delivery
O	1338	1340	of
O	1341	1351	ophthalmic
O	1352	1356	care
O	1357	1359	to
O	1360	1368	patients
O	1369	1373	with
B-Disease	1374	1382	diabetes
O	1383	1388	would
O	1389	1394	yield
O	1395	1406	substantial
O	1407	1416	financial
O	1417	1420	and
O	1421	1427	visual
O	1428	1435	savings
O	1435	1436	,
O	1437	1441	thus
O	1442	1448	making
O	1449	1454	major
O	1455	1466	recruitment
O	1467	1475	programs
O	1476	1480	such
O	1481	1483	as
O	1484	1487	the
O	1488	1496	National
O	1497	1500	Eye
O	1501	1510	Institute
O	1510	1511	'
O	1511	1512	s
O	1513	1521	National
O	1522	1525	Eye
O	1526	1532	Health
O	1533	1542	Education
O	1543	1550	Program
O	1551	1554	and
O	1555	1558	the
O	1559	1567	American
O	1568	1575	Academy
O	1576	1578	of
O	1579	1592	Ophthalmology
O	1592	1593	'
O	1593	1594	s
B-Disease	1595	1603	Diabetes
O	1604	1608	2000
O	1608	1609	,
O	1610	1614	both
O	1615	1627	economically
O	1628	1631	and
O	1632	1642	clinically
O	1643	1652	effective
O	1652	1653	.
